Effects of adiponectin deficiency on structural and metabolic remodeling in mice subjected to pressure overload.

Recent data suggest adiponectin, an adipocyte-derived hormone, affects development of heart failure in response to hypertension. Severe short-term pressure overload [1-3 wk of transverse aortic constriction (TAC)] in adiponectin(-/-) mice causes greater left ventricle (LV) hypertrophy than in wild-type (WT) mice, but conflicting results are reported regarding LV remodeling, with either increased or decreased LV end diastolic volume compared with WT mice. Here we assessed the effects of prolonged TAC on LV hypertrophy and remodeling. WT and adiponectin(-/-) mice were subjected to TAC and maintained for 6 wk. Regardless of strain, TAC induced similar LV hypertrophy ( approximately 70%) and upregulation of mRNA for heart failure marker genes. However, LV chamber size was dramatically different, with classic LV dilation in WT TAC mice but concentric LV hypertrophy in adiponectin(-/-) mice. LV end diastolic and systolic volumes were lower and ejection fraction higher in adiponectin(-/-) TAC mice compared with WT, indicating that adiponectin deletion prevented LV remodeling and deterioration in systolic function. The activities of marker enzymes of mitochondrial oxidative capacity were reduced in WT TAC mice by approximately 35%, whereas enzyme activities were maintained at sham levels in adiponectin(-/-) TAC mice. In conclusion, in WT mice, long-term pressure overload caused dilated LV hypertrophy accompanied by decreased activity of mitochondrial oxidative enzymes. Although adiponectin deletion did not affect LV hypertrophy, it prevented LV chamber remodeling and preserved mitochondrial oxidative capacity, suggesting that adiponectin plays a permissive role in mediating changes in cardiac structure and metabolism in response to pressure overload.

[1]  K. Walsh,et al.  What can adiponectin say about left ventricular function? , 2009, Heart.

[2]  Fen Liu,et al.  Downregulation of survival signalling pathways and increased apoptosis in the transition of pressure overload‐induced cardiac hypertrophy to heart failure , 2009, Clinical and experimental pharmacology & physiology.

[3]  D. Levy,et al.  Resistin, adiponectin, and risk of heart failure the Framingham offspring study. , 2009, Journal of the American College of Cardiology.

[4]  W. Harris,et al.  Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. , 2009, Cardiovascular research.

[5]  G. Dorn Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling. , 2008, Cardiovascular research.

[6]  W. Kop,et al.  The antioxidant tempol attenuates pressure overload-induced cardiac hypertrophy and contractile dysfunction in mice fed a high-fructose diet. , 2008, American journal of physiology. Heart and circulatory physiology.

[7]  K. O’Shea,et al.  Transient activation of p38 MAP kinase and up-regulation of Pim-1 kinase in cardiac hypertrophy despite no activation of AMPK. , 2008, Journal of molecular and cellular cardiology.

[8]  M. Quon,et al.  Leptin and Cardiovascular Disease: Response to Therapeutic Interventions , 2008, Circulation.

[9]  W. Kop,et al.  Low-carbohydrate/high-fat diet attenuates pressure overload-induced ventricular remodeling and dysfunction. , 2008, Journal of cardiac failure.

[10]  W. Kop,et al.  Dietary supplementation with omega-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload. , 2007, Cardiovascular research.

[11]  Takeshi Kimura,et al.  Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[12]  K. Walsh,et al.  Adiponectin actions in the cardiovascular system. , 2007, Cardiovascular research.

[13]  J. McMurray,et al.  Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. , 2007, European heart journal.

[14]  K. Kadota,et al.  PJ-604 Long-Term Clinical Outcome of Treating Bifurcation Lesions with Sirolimus-Eluting Stent Using Two Stent Technique(Coronary revascularization, PCI-16, The 71st Annual Scientific Meeting of the Japanese Circulation Society) , 2007 .

[15]  M. Quon,et al.  Adiponectin and cardiovascular disease: response to therapeutic interventions. , 2007, Journal of the American College of Cardiology.

[16]  G. Dorn,et al.  Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. , 2007, Physiology.

[17]  M. Quon,et al.  Adiponectin and cardiovascular disease: response to therapeutic interventions. , 2007, Journal of the American College of Cardiology.

[18]  S. Cummings,et al.  Serum adiponectin and coronary heart disease risk in older Black and White Americans. , 2006, The Journal of clinical endocrinology and metabolism.

[19]  M. Kawakami,et al.  Association of hyperadiponectinemia with severity of ventricular dysfunction in congestive heart failure. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[20]  K. Walsh,et al.  Targeting adiponectin for cardioprotection , 2006, Expert opinion on therapeutic targets.

[21]  E. Ingelsson,et al.  Adiponectin and risk of congestive heart failure. , 2006, Journal of the American Medical Association (JAMA).

[22]  Y. Sharabi,et al.  Circulating adiponectin concentrations in patients with congestive heart failure , 2006, Heart.

[23]  A. Gradman,et al.  From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. , 2006, Progress in cardiovascular diseases.

[24]  Jan Frystyk,et al.  Plasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart Failure , 2005, Circulation.

[25]  S. Kihara,et al.  Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2–dependent mechanisms , 2005, Nature Medicine.

[26]  T. Funahashi,et al.  Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. , 2005, Cardiovascular research.

[27]  William C Stanley,et al.  Myocardial substrate metabolism in the normal and failing heart. , 2005, Physiological reviews.

[28]  H. Lodish,et al.  The role of the adipocyte hormone adiponectin in cardiovascular disease. , 2005, Current opinion in pharmacology.

[29]  S. Kihara,et al.  Adiponectin-mediated modulation of hypertrophic signals in the heart , 2004, Nature Medicine.

[30]  T. Ogihara,et al.  Hypoadiponectinemia Is an Independent Risk Factor for Hypertension , 2004, Hypertension.

[31]  S. Kihara,et al.  Adiponectin Stimulates Angiogenesis by Promoting Cross-talk between AMP-activated Protein Kinase and Akt Signaling in Endothelial Cells* , 2004, Journal of Biological Chemistry.

[32]  E. Abel,et al.  Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. , 2003, American journal of physiology. Heart and circulatory physiology.

[33]  S. Kihara,et al.  Association of Hypoadiponectinemia With Coronary Artery Disease in Men , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[34]  S. Uchida,et al.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.

[35]  William C Stanley,et al.  Impaired Myocardial Fatty Acid Oxidation and Reduced Protein Expression of Retinoid X Receptor-&agr; in Pacing-Induced Heart Failure , 2002, Circulation.

[36]  M. Matsuda,et al.  Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 , 2002, Nature Medicine.

[37]  R. Visse,et al.  Matrix Metalloproteinases Regulation and Dysregulation in the Failing Heart , 2002 .

[38]  J. C. Gomez,et al.  Impaired Myocardial Fatty Acid Oxidation and Reduced Protein Expression of Retinoid X Receptor-alpha in Pacing-Induced Heart Failure , 2002 .

[39]  C. Benedict,et al.  Effects of Dopamine β-Hydroxylase Inhibition With Nepicastat on the Progression of Left Ventricular Dysfunction and Remodeling in Dogs With Chronic Heart Failure , 2000 .

[40]  C. Benedict,et al.  Effects of dopamine beta-hydroxylase inhibition with nepicastat on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. , 2000, Circulation.